Investigational drug · Phase 2
HRS-4729
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Metabolic Dysfunction-Associated Steatohepatitis (MASH), Type 2 Diabetes, Overweight or Obesity.
Phase 2Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
5
Any phase or sponsor naming "HRS-4729"
First trial start
2026
Jul 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HRS-4729", any sponsor or status.
Conditions studied
As listed on its trial records.
- Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Type 2 Diabetes
- Overweight or Obesity
Approved drugs for the same conditions: Type 2 diabetes · Obesity and weight management · MASH (fatty liver disease) · Cardiovascular and metabolic · Infectious disease and vaccines · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "HRS-4729" as an intervention, largest first.
- A Study to Evaluate the Efficacy and Safety of HRS-4729 Injection in ObesityPivotal-lookingNot yet recruiting
Fujian Shengdi Pharmaceutical Co., Ltd.Industry
NCT07690826 · 252 participants (planned) · Start Jul 2026 · Primary completion Mar 2027
Drug: HRS-4729 Injection; HRS-4729 Injection and 5 more · For: Overweight or Obesity
Sites: Shanghai, China
- A Study of HRS-4729 Injection in Participants With Type 2 DiabetesPivotal-lookingNot yet recruiting
Fujian Shengdi Pharmaceutical Co., Ltd.Industry
NCT07843862 · 240 participants (planned) · Start Oct 2026 · Primary completion Apr 2027
Drug: HRS-4729 Injection; Mazdutide and 1 more · For: Type 2 Diabetes
Sites: Wuhan, China; Tianjin, China
- A Study of HRS-4729 Injection and HRS9531 Injection in Participants With Metabolic Dysfunction-Associated SteatohepatitisPivotal-lookingRecruiting
Fujian Shengdi Pharmaceutical Co., Ltd.Industry
NCT07660848 · 160 participants (planned) · Start Aug 14, 2026 · Primary completion Mar 2028
Drug: HRS-4729 Injection; HRS9531 Injection and 2 more · For: Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Sites: Beijing, China; Zhengzhou, China
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-4729 Injection in Healthy SubjectsPivotal-lookingCompleted
Fujian Shengdi Pharmaceutical Co., Ltd.Industry
NCT06762600 · 102 participants · Start Jan 16, 2025 · Primary completion Mar 12, 2026
Drug: HRS-4729 injection; HRS-4729 injection placebo and 3 more · For: Overweight or Obesity
Sites: Jinan, China
Fujian Shengdi Pharmaceutical Co., Ltd.Industry
NCT07807059 · 32 participants (planned) · Start Sep 9, 2026 · Primary completion Mar 15, 2027
Drug: HRS-4729 · For: Overweight/Obesity; Metabolic Dysfunction-associated Steatotic Liver Disease/Steatohepatitis (MASLD/MASH); Type 2 Diabetes Mellitus
Sites: Chengdu, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- HRS9531Phase 313 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- UBT251Phase 310 trials
The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2
- IBI362Phase 38 trials
Innovent Biologics (Suzhou) Co. Ltd. · Obesity, Overweight, Sleep Apnea
- PemvidutidePhase 34 trials
Altimmune, Inc. · Alcohol-associated Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Alcohol Use Disorder (AUD)
- QL2401Phase 21 trial
Qilu Pharmaceutical Co., Ltd. · Metabolic Dysfunction-associated Steatohepatitis (MASH)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.